At 29 weeks pregnant, Kiersten Rapplean was supposed to be counting down the weeks until she met her second son.
There were already all the familiar things that fill the final stretch of pregnancy: appointments, preparations, conversations about the baby, thoughts about how life would change when a second child joined the family.
Instead, in February 2024, her life abruptly divided into two timelines.
There was the future she had been imagining.
And there was the future doctors were suddenly asking her to fight for.
Kiersten, then 32 and living in Missouri, learned that she had an aggressive form of breast cancer while nearly seven months pregnant. She later described her diagnosis as Stage IV, estrogen- and progesterone-receptor-negative, HER2-positive inflammatory invasive ductal carcinoma.
It was not the kind of cancer diagnosis that could simply be placed on hold until after her baby arrived.
Within weeks, she was receiving chemotherapy while still pregnant.
Then came an induced delivery, a newborn needing care in the neonatal intensive care unit, additional cancer treatment only days after childbirth, more chemotherapy, major surgery and continuing therapy.
More than two years later, in July 2026, Missouri television station KSDK reported a milestone that once might have seemed impossibly distant: Rapplean was being described as cancer-free.
For a woman who had written about wanting nothing more extraordinary than to attend birthday parties, read bedtime stories and watch her boys grow up, it represented something deeply personal.
It meant more time.
More ordinary mornings.
More birthdays.
And a future that, in the darkest days of 2024, had suddenly seemed frighteningly uncertain.
A Diagnosis During Pregnancy
Rapplean later laid out much of her treatment timeline publicly in a fundraiser she organized in September 2024.
She wrote that she was pregnant with her second son, Travis, when she was diagnosed in February at 29 weeks of pregnancy. She was already a mother to an older boy, Emmett.
The diagnosis was especially complicated because of the kind of breast cancer involved.
Inflammatory breast cancer, or IBC, is rare, accounting for roughly 1% to 5% of breast cancers in the United States, according to the National Cancer Institute. Unlike many breast cancers that may first be noticed as a distinct lump, inflammatory breast cancer can cause rapid swelling, redness and changes to the skin because cancer cells block lymph vessels in the breast.
It is also fast-growing.
The NCI explains that inflammatory breast cancer is always considered at least Stage III at diagnosis. When it has spread to distant parts of the body, it is classified as Stage IV.
Rapplean's cancer was also HER2-positive.
HER2 is a protein involved in cell growth. Some breast cancer cells produce excessive amounts of it, which can help the cancer grow and spread more aggressively. Approximately 15% to 20% of breast cancers are HER2-positive, according to the American Cancer Society. The development of medicines specifically targeting HER2 has significantly expanded treatment options for these cancers.
Yet pregnancy complicated virtually every decision.
Doctors were not treating only a cancer patient.
They were caring for a pregnant woman whose unborn baby was still developing.
Cancer Treatment Cannot Always Wait for Delivery
Breast cancer during pregnancy is unusual, but it is not unheard of.
The National Cancer Institute estimates breast cancer occurs in approximately one out of every 3,000 pregnancies, most often among women between 32 and 38 years old. Treatment is possible during pregnancy, but doctors may need to modify both the type and timing of therapy based on the trimester, cancer stage and individual circumstances.
That distinction became critical for Rapplean.
There is a common assumption that chemotherapy and pregnancy can never overlap.
Modern evidence is more nuanced.
Chemotherapy is generally avoided during the first trimester, when major fetal organs are developing. However, certain chemotherapy medicines can be administered during the second and third trimesters. The American Cancer Society says drugs including doxorubicin and cyclophosphamide have been used during these later stages without evidence of increased birth defects, although treatment may be associated with risks such as premature delivery.
The NCI similarly states that anthracycline-based chemotherapy has been used during the second and third trimesters, while chemotherapy is normally stopped several weeks before delivery so the mother's blood counts can recover and risks surrounding childbirth can be reduced.
Rapplean began treatment.
According to her own account, she received two rounds of AC chemotherapy while pregnant. AC commonly refers to the combination of doxorubicin and cyclophosphamide, both well-established breast cancer drugs.
Every infusion now occurred against an unusual emotional backdrop.
Cancer treatment is physically demanding even without pregnancy. But Rapplean was undergoing treatment while feeling her baby continue to grow inside her.
She was preparing simultaneously for birth and for the possibility of prolonged cancer treatment.
There was no clean separation between the two experiences.
Motherhood and oncology had suddenly become intertwined.
March 25, 2024: Travis Arrives
By late March, Rapplean had reached 36 weeks of pregnancy.
On March 24, she celebrated her birthday.
One day later, on March 25, doctors induced labor at 36 weeks and one day.
Travis was born weighing 6 pounds, 8 ounces and measuring 19.75 inches, according to Rapplean's account.
For most new mothers, childbirth is followed by a period centered almost entirely on recovery and caring for the newborn.
Kiersten's situation was different.
Travis needed additional lung support and spent 17 days in the neonatal intensive care unit, she wrote.
Meanwhile, his mother's cancer treatment could not stop.
The day after giving birth, Rapplean underwent imaging that had been deferred while she was pregnant. She later said those scans helped determine the full stage of her disease.
That detail helps explain an apparent inconsistency sometimes found in shortened social-media versions of her story. Rapplean described herself as having been diagnosed with Stage IV cancer while 29 weeks pregnant, but she also wrote that the scans performed after delivery determined her staging.
A more precise description is therefore that she was diagnosed with inflammatory HER2-positive breast cancer during pregnancy, while some of the imaging needed to establish the full extent of the disease was completed postpartum.
Then, only three days after delivering Travis, treatment intensified again.
Three Days After Giving Birth, Treatment Resumed
Rapplean said she began treatment specifically targeting the biology of her HER2-positive cancer three days after childbirth.
For HER2-positive breast cancer, medicines such as trastuzumab and pertuzumab can target the HER2 protein and interfere with signals that help cancer cells grow.
These drugs illustrate why delivery mattered medically.
HER2-targeted treatments are generally avoided during pregnancy because they can harm the fetus. The American Cancer Society specifically advises that drugs such as trastuzumab and pertuzumab are not considered safe during pregnancy.
Once Travis had been born, however, doctors had access to treatment options that could not safely have been used while he was still in the womb.
Rapplean subsequently underwent five rounds of TCHP chemotherapy, completing them on June 20, 2024, according to her fundraiser.
TCHP generally refers to a combination of docetaxel, carboplatin, trastuzumab and pertuzumab—a regimen combining conventional chemotherapy with therapies directed against HER2.
The distinction is important because social-media retellings sometimes refer broadly to all of Rapplean's later treatment as “immunotherapy.” In conventional oncology terminology, trastuzumab and pertuzumab are most commonly described as HER2-targeted therapies, although monoclonal antibodies can also interact with the immune system.
Whatever the terminology, the schedule was relentless.
Pregnancy.
Chemotherapy.
Delivery.
NICU.
More treatment.
There was little space between milestones.
A Double Mastectomy
On July 11, 2024, less than four months after giving birth, Rapplean underwent a double mastectomy, according to the timeline she published.
By then, she had spent much of the year moving between medical appointments and treatments while adapting to life with a newborn and an older child.